ABSTRACT
BACKGROUND AND OBJECTIVES: Minimizing the transmission risk of infectious diseases is of primary importance in the manufacture of products derived from human plasma. A novel chromatography-based intravenous immunoglobulin (IGIV) manufacturing process was developed and the reduction of virus and transmissible spongiform encephalopathies (TSE) during the manufacturing process was assessed. Mechanistically distinct steps that could affect virus reduction were identified, and the robustness of virus reduction over the range of process conditions was determined. MATERIALS AND METHODS: Virus and TSE reduction by processing steps were assessed using a scaled-down version of the IGIV manufacturing process. RESULTS: Virus and TSE reduction at manufacturing process set points were well within safety standards. Robustness studies verified that the reproducibility of virus reduction was maintained at or beyond operating parameter extremes. Virus reduction across two combined manufacturing steps was lower than the sum of virus-reduction values across the individual steps, indicating mechanistic similarity of the two steps with respect to virus reduction. Only reduction from mechanistically distinct steps was claimed. CONCLUSIONS: This comprehensive approach to pathogen safety provides the new immunoglobulin manufacturing process with a detailed, yet realistic, assessment of the risk of transmission of infectious pathogens.
Subject(s)
Disinfection/methods , Drug Industry/methods , Immunoglobulins, Intravenous/standards , Prions/isolation & purification , Viruses/isolation & purification , Caprylates/pharmacology , Chemical Precipitation , Chromatography , Disinfection/standards , Drug Contamination/prevention & control , Drug Industry/standards , Filtration , Humans , Manufactured Materials/standards , Manufactured Materials/virology , Prion Diseases/prevention & control , Prion Diseases/transmission , Virus Diseases/prevention & control , Virus Diseases/transmissionABSTRACT
BACKGROUND AND OBJECTIVES: Current manufacture of intravenous immunoglobulin (Gamimune N) uses four cold-ethanol precipitation steps and solvent-detergent treatment. Our objective was to design a new manufacturing process to maximize immunoglobulin G (IgG) purity, achieve robust viral safety, preserve all the biological activities of antibody and avoid unnecessary protein loss. MATERIALS AND METHODS: The new process combines multiple functions in single steps. Caprylate is added to precipitate non-IgG proteins and to inactivate enveloped viruses. Two successive anion-exchange columns are used to purify IgG and remove caprylate. The new product, IGIV-C (Gamunex, 10%) is formulated with glycine at 100 mg/ml IgG, pH 4.25. Vials are incubated for 21 days at 23-27 degrees C in a final virus-inactivation step. RESULTS: Compared with the process for production of Gamimune N, that for IGIV-C requires a shorter production time, achieves more robust virus inactivation, increases IGIV yield from plasma, improves physiological IgG subclass distribution (resulting in higher levels of IgG4), and improves purity, with lower levels of IgA (40 microg/ml), IgM (< 2 microg/ml) and albumin (< 20 microg/ml). Antibody binding, opsonization and protective activities are similar. CONCLUSIONS: Compared with the current commercial process, the new IGIV-C manufacturing process produces a more highly purified preparation that contains slightly higher levels of IgG4 and retains antibody activities required for clinical efficacy.
Subject(s)
Disinfection/methods , Immunoglobulins, Intravenous/standards , Viruses/isolation & purification , Animals , Bacterial Infections/drug therapy , Caprylates/pharmacology , Chemical Precipitation , Chromatography , Disinfection/standards , Drug Contamination/prevention & control , Drug Industry/methods , Drug Industry/standards , Humans , Immunoglobulins, Intravenous/analysis , Immunoglobulins, Intravenous/pharmacology , Mice , Survival Rate , Virus Diseases/prevention & control , Virus Diseases/transmissionABSTRACT
Solvent-detergent treatment, although used routinely in plasma product processing to inactivate enveloped viruses, substantially reduces product yield from the human plasma resource. To improve yields in plasma product manufacturing, a new viral reduction process has been developed using the fatty acid caprylate. As licensure of plasma products warrants thorough evaluation of pathogen reduction capabilities, the present study examined susceptibility of enveloped viruses to inactivation by caprylate in protein solutions with varied pH and temperature. In the immunoglobin-rich solutions from Cohn Fraction II+III, human immunodeficiency virus, Type-1, bovine viral diarrhea virus (BVDV), and pseudorabies virus were inactivated by caprylate concentrations of >/=9 mM, >/=12 mM, and >/=9 mM, respectively. Compared to solvent-detergent treatment, BVDV inactivation in Fraction II+III solution was significantly faster (20-60 fold) using 16 mM caprylate. Caprylate-mediated inactivation of BVDV was not noticeably affected by temperature within the range chosen manufacturing the immunoglobulin product. In Fraction II+III solutions, IgG solubility was unaffected by =19 mM caprylate. In albumin solution from Cohn supernatant IV-1, 40 mM caprylate rapidly inactivated BVDV, demonstrating versatility in inactivating enveloped viruses potentially present in other protein solutions. Our data show that caprylate is a robust enveloped virus inactivating agent for immunoglobulins and albumin which may potentially be utilized for other proteins; viral inactivation was not adversely affected by protein content and the buffer composition conditions evaluated. Within the parameters examined, caprylate inactivation of enveloped viruses provided comparable activity or advantages relative to the current, standard solvent-detergent treatment.
Subject(s)
Caprylates/pharmacology , Detergents/pharmacology , Sterilization/methods , Virus Inactivation , Viruses/isolation & purification , Albumins/metabolism , Blood-Borne Pathogens , Chromatography, Gas , Chromatography, Ion Exchange , HIV-1/isolation & purification , Hydrogen-Ion Concentration , Immunoglobulin A/blood , Immunoglobulin A/metabolism , Immunoglobulin G/blood , Immunoglobulin M/blood , Kinetics , Lipids/chemistry , Nephelometry and Turbidimetry , Sodium Cholate/pharmacology , Solvents/pharmacology , Temperature , Time Factors , Virus Diseases/prevention & controlABSTRACT
BACKGROUND AND OBJECTIVES: Alpha-proteinase inhibitor (PI) protects the lungs from proteolytic damage caused by elastase and can be used to treat congenital emphysema. We describe an improved method of purification of alpha 1 PI from redissolved fraction IV-1 paste. MATERIALS AND METHODS: The process used dimethylaminoethyl anion exchange chromatography, sulfopropyl cation exchange chromatography, virus inactivation by dry heat, and tri-n-butyl-phosphate/cholate treatment, followed by a second strong cation exchange chromatography. Optimizations of loading conditions for ion exchange chromatography at small scale (20-60 ml of suspension) are described. Virus inactivation was adjusted to provide the best yield of alpha 1 PI consistent with effective inactivation. The process has been effectively scaled up. RESULTS: The final product was approximately 90% pure by SDS-PAGE, with a 60-70% yield from starting fraction IV-1 paste. The process has been characterized by methods including nonreduced SDS-PAGE, alpha 1 PI inhibition assay, and biuret protein assay. CONCLUSION: The method described is an effective way of preparing large quantities of alpha 1 PI from fractionated plasma.
Subject(s)
Blood Proteins/chemistry , Chromatography, Ion Exchange/methods , alpha 1-Antitrypsin/isolation & purification , Anions , Cations , Cholates/pharmacology , Chromatography, DEAE-Cellulose/methods , Detergents/pharmacology , Electrophoresis, Polyacrylamide Gel , Humans , Hydrogen-Ion Concentration , Molecular Weight , Organophosphates/pharmacology , Pilot Projects , Protein Structure, Tertiary , Sodium Dodecyl Sulfate , Solvents/pharmacology , Sterilization/methods , Temperature , Virus Activation , Viruses/drug effects , Viruses/growth & development , Water , alpha 1-Antitrypsin/chemistryABSTRACT
A novel chromatographic process for purification of alpha 1 proteinase inhibitor (alpha 1-PI) from Cohn fraction IV-1 paste is described. This process has been successfully scaled up to 50-1 columns. It involves DEAE chromatography, sulfopropyl (S) cation chromatography, tri-n-butyl phosphate (TNBP)-cholate treatment, a second S cation chromatography, freeze-drying and dry-heat. The process has been optimized for purity, yield, lipid removal, chemical usage and water consumption. Filtration after TNBP-cholate treatment plays a key role in ensuring a low lipid content in the final product. Pre-equilibration with high salt buffer is necessary to reduce the water consumption significantly during the ion-exchange chromatography equilibration step. The final product is approximately 95% pure by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, with a 64% to 70% yield from IV-1 paste.
Subject(s)
Blood Proteins/chemistry , Chromatography, DEAE-Cellulose/methods , Serine Proteinase Inhibitors/isolation & purification , alpha 1-Antitrypsin/isolation & purification , Cholesterol/analysis , Cholesterol/isolation & purification , Cholic Acid , Cholic Acids/analysis , Cholic Acids/chemistry , Cholic Acids/isolation & purification , Electrophoresis, Polyacrylamide Gel , Humans , Organophosphates/analysis , Organophosphates/chemistry , Organophosphates/isolation & purification , Reproducibility of Results , Serine Proteinase Inhibitors/metabolism , alpha 1-Antitrypsin/metabolismABSTRACT
We describe an improved method for large-scale purification of antithrombin III (AT-III) from human plasma involving heparin affinity chromatography of redissolved fraction IV-1 paste, viral inactivation by heating, followed by a second heparin affinity column. The characteristics of a new heparin affinity resin and the ability to extrapolate process behavior from small-scale (20 ml) to large-scale (40 liter) columns are described. This supports the use of the small-scale column for process optimization and validation studies in compliance with current regulatory requirements for biological products. The process has been characterized by analytical techniques including sodium dodecyl sulfate (SDS), reducing SDS, and nondenaturing polyacrylamide gel electrophoresis; laser desorption time-of-flight mass spectroscopy, and electrospray mass spectroscopy. These results demonstrate that greater than 95% of the protein in the final products is AT-III, which is greater than 95% active as defined by thrombin inhibition.